Prospective Cohort of Patients With Hepatocellular Carcinoma in France

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-26

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatocellular carcinoma (HCC) occurs in 90% of cirrhosis primary liver cancers. In France, 8,500 new cases of HCC occur each year, and about 8,000 deaths per year are related to this cancer. The 5-year survival rate is 10%, one of the lowest survival rates of all cancer types. HCC raises a number of major challenges: HCC is discovered at a curable stage in only 25% of cases, reflecting the marked delay in the diagnosis of early stages. The state of knowledge about HCC is well behind that of other cancers (no biomarker, complex carcinogenesis, influence of the aetiology, poorly valorised data, etc.). Rapid technological progress requires large-scale studies to evaluate new diagnostic and therapeutic modalities.

The CHIEF project constitutes a common basis knowledge for research project using prospectively collected data in patients with HCC, regardless of the cause and stage of the cancer.

This project is a Multicentre longitudinal observational study of patients with HCC with prospective data collection on inclusion and patient follow-up. Constitution of a biological resources collection. 5,000 patients will be included over 2 years with a follow-up of patients of 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Influence of Social Determinants of Health on the Management of HCC in the French National Cohort Study CHIEF

NCT05128123

Hepatocellular Carcinoma

ACTIVE_NOT_RECRUITING

FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.

NCT05095714

Hepatocellular Carcinoma Liver Cancer Cirrhosis +1 more

NOT_YET_RECRUITING NA

Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis

NCT00190385

Compensated Cirrhosis

COMPLETED PHASE3

Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease

NCT03307408

Hepatocellular Carcinoma

UNKNOWN

Use of the French Healthcare Insurance Database

NCT02983968

Cirrhosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer of Liver Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* New cases of HCC
* suspected case of HCC regardless of the cause, stage, treatment
* Known HCC: drug treatment for recurrence or progression

Exclusion Criteria

* Associated serious condition threatening life in the short term (with the exception of liver disease itself)
* So-called vulnerable populations: minors, persons under guardianship or temporary guardianship, or person deprived of their liberty by an administrative or judicial decision

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No